Let's not ignore the separation of Encore (primary revenue generator, which ex-CEO Sarvis now runs without SHOM headaches) from SHOM, which now only includes the ApneaRX business (a minor business with nothing proprietary; just rental of breathing equipment and some other hardware, probably mostly for Medicare or Medicaid patients).
The ex-CEO's LinkedIn profile shows him affiliated only with Encore now, and CEO at SHOM as a previous job). Check it out!
Ladies and Gentlemen, do not be fooled by shenanigans and lofty projections. This is not an "easy 10bagger" blah blah blah "no brainer" blah blah or even a "to the moon, Alice, to the moon" shot.
Moderate your expectations on this one or you will overbuy. The volume is not there lately to justify any large purchase.
JMHO,
stockpeeker